

# Tobias Janowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6137892/publications.pdf>

Version: 2024-02-01

27  
papers

4,721  
citations

567281

15  
h-index

580821

25  
g-index

32  
all docs

32  
docs citations

32  
times ranked

8033  
citing authors

#	ARTICLE	IF	CITATIONS
1	Carcinomas assemble a filamentous CXCL12â€“keratin-19 coating that suppresses T cellâ€“mediated immune attack. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	32
2	Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. Gut, 2022, 71, 879-888.	12.1	24
3	Training the host organism to enhance anti-cancer immunity. Cancer Cell, 2022, , .	16.8	1
4	Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. Oncologist, 2021, 26, 269-273.	3.7	22
5	AMD3100/Plerixafor overcomes immune inhibition by the CXCL12â€“KRT19 coating on pancreatic and colorectal cancer cells. British Journal of Cancer, 2021, 125, 149-151.	6.4	11
6	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 879-887.	3.7	12
7	CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer. Clinical Cancer Research, 2021, 27, 1381-1390.	7.0	9
8	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28960-28970.	7.1	150
9	The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research. Cancer Discovery, 2020, 10, 913-915.	9.4	0
10	Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, 69, 1592-1597.	12.1	106
11	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	28.4	2,012
12	Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report. BMC Cancer, 2020, 20, 38.	2.6	6
13	Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate. JNCI Cancer Spectrum, 2019, 3, pkz068.	2.9	6
14	Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Gastroenterology, 2019, 157, 1413-1428.e11.	1.3	57
15	A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. Journal of Allergy and Clinical Immunology, 2018, 142, 311-314.e6.	2.9	13
16	A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Seminars in Oncology, 2018, 45, 170-175.	2.2	17
17	Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 2018, 23, 116-117.	3.7	3
18	Cancer: The Tumor-Driven Disease of the Host. Cell Metabolism, 2018, 28, 5-6.	16.2	13

#	ARTICLE	IF	CITATIONS
19	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	6.7	55
20	A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Seminars in Oncology, 2017, 44, 136-140.	2.2	183
21	New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. Journal of Clinical Oncology, 2017, 35, 2798-2805.	1.6	78
22	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism, 2016, 24, 672-684.	16.2	264
23	Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. British Journal of Cancer, 2016, 114, 381-387.	6.4	56
24	Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy. BMC Research Notes, 2015, 8, 524.	1.4	4
25	Panhypopituitarism secondary to a solitary hypothalamic metastasis. BMJ Case Reports, 2014, 2014, bcr2014204283-bcr2014204283.	0.5	2
26	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20212-20217.	7.1	1,482
27	Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future. Seminars in Oncology, 2013, 40, 482-491.	2.2	94